natural pharmaceuticals derived From Cannabis and other medicinal plants
Recently Received Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR topical product
AGORACOM NEWS FLASH
MUST WATCH INTERVIEWS THIS WEEK!
Message: Tetra Bio-Pharma Strengthens Management Team
OTTAWA, ONTARIO--(May 10, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF), today announced that it has strengthened its management team with the appointment of Robert Bechard to the position of Vice President, Finance and Business Development, effective today, May 10, 2017.
Mr. Bechard brings more than 20 years' experience in the biopharmaceutical industry having worked for two lifescience venture capital funds, a pharmaceutical R&D management firm, a drug delivery company, and as a consultant to the biotech industry. As Vice President of Finance and Business Development, Mr. Bechard will be responsible for leading the charge on business development as it relates to the pharmaceutical side of the business and managing the financial side of the company.
During his tenure at RBC Lifesciences Funds I&II, Mr. Bechard was a member of the Senior Management team that delivered top quartile returns in two separate funds. RBC Lifesciences. During his 12-year term as a venture capitalist Mr. Bechard, made numerous investments, sat on the boards of more than 25 life science companies and was actively involved in the negotiation of numerous strategic alliances, partnerships, and outright sales to both pharmaceutical and biotech companies. As a Board member he played an active role in the negotiation of numerous exits and was also actively involved in taking several companies public in Canada and the U.S. In his two operating roles, he was instrumental in contributing to the growth of two companies actively involved in developing pharmaceuticals. As a consultant to the biopharmaceutical industry Mr. Bechard provided start-up companies with assistance in the areas of fundraising, business development and corporate development.
"We are most pleased to welcome Bob to the team as we are focused on building Tetra as a leading bio-pharmaceutical organization," said Andre Rancourt, CEO of Tetra Bio-Pharma. "Mr. Bechard has built great relations over his career in the pharmaceutical industry which will open new opportunities to further expand our product pipeline through partnerships as we build Tetra into a global leader in pharmaceutical cannabis."
About Tetra Bio Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE: TBP) (OTCQB: GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
The Canadian Securities Exchange ("CSE") has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Vice President, IR & Corporate Communications
Please login to post a reply